Swiss generic and biosimilars drugmaker Sandoz today revealed that Francisco Ballester, president Region International and a ...

Novartis’ generics unit Sandoz will tell investors today that it can add $3 billion in annual sales from the launch of new products, after it spins out of its parent company later this year.

“Because of [our] credentials of being first to market with many biosimilars and generic products, we were selected by Sandoz to do this transaction in Colombia,” he explained. “They decided ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

Sandoz Group said it would pay $275 million to settle claims from some plaintiffs in a generics drug pricing antitrust lawsuit in the U.S. The Swiss generics-medicine company said Tuesday that it ...

Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history ...

Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Europe ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of servicePeter Stenico, ...

(RTTNews) - Swiss generic pharmaceutical company Sandoz Group AG (SDZNY) announced on Monday that Peter Stenico has been appointed as the new President Region International and member of the ...